Consortium focuses on new mouse models of human cancers

December 27, 1999

NASHVILLE, Tenn - Scientists from the Vanderbilt-Ingram Cancer Center have been selected to participate in the National Cancer Institute's new Mouse Models of Human Cancers Consortium.

The NCI announced formation of the Consortium, including 19 groups from more than 30 U.S. institutions, on Dec. 28. These groups will work separately to develop and evaluate mouse models to parallel the development and progression of human cancers of eight major organ systems - breast, prostate, lung, ovary, skin, blood and lymph system, colon and brain. They will share their findings and work together to set research priorities and overcome technological obstacles.

The selection brings $2.5 million in funding over the next five years for VICC scientists' work in mouse models for breast, prostate, colon and pancreatic cancer. More important than the money, however, is the participation that Vanderbilt will have in setting priorities for mouse model research in the coming years, said Bob Coffey, M.D., Ingram Professor of Cancer Research and principal investigator in the project.

"This is an important priority for NCI director Dr. Richard Klausner," Coffey said. "The initial plan called for six centers to be selected and funded. When the 32 proposals came in, they were reviewed by a group of investigators, who awarded Vanderbilt's application the second-highest score. So we were assured a place at the table. However, Dr. Klausner was so excited about the quality of the applications and the possibilities that could emerge from this Consortium, he identified additional funds to expand the group from six to 19."

The development of mouse models of human cancer, through various sophisticated genetic engineering techniques, is critical to unlocking more of the mysteries of how cancer develops. As scientists learn more about the many genetic steps involved in the process, the goal is to use that knowledge to develop methods to cure cancer and ultimately to prevent it.

The VICC's proposal is a collective endeavor involving more than 20 investigators at Vanderbilt, said Coffey. Co-principle investigators in the grant are Harold Moses, M.D., Benjamin F. Byrd Professor of Oncology and director of the VICC; Robert Matusik, M.D., professor of Urologic Surgery and Cell Biology; and David Threadgill, Ph.D., assistant professor of Cell Biology and Medicine.

The VICC's grant application focused a great deal on work with the type 2 receptor for transforming growth factor beta (TGFb) in colon, prostate and breast cancer. "We are focusing on the down-regulation or elimination of this receptor and then examining implications of such manipulations for cancer development," Coffey said.

TGFb, identified and reported by Moses' Mayo Clinic research team before he joined the Vanderbilt faculty in 1985, is a powerful regulator of cell growth. One of its primary jobs is to instruct cells not to divide. The type 2 receptor is the cellular doorway through which cells "hear" this signal. TGFb is increasingly becoming a focus for cancer researchers. Recently, an abnormally low expression of this receptor was recently identified by VICC investigators as a marker for increased cancer risk in women with a type of benign breast disease called hyperplasia. Additional abnormalities in the TGFb signaling pathway have been linked to cancer development in these breast, prostate, colon and pancreas.

The VICC scientists have developed mouse models for down-regulated TGFb receptor expression in the breast, prostate and colon, with evidence already suggesting premalignant and malignant changes in the breast, premalignant changes in the prostate and acceleration of carcinogen-induced colon cancer, Coffey said. "Our goal is to develop and validate mouse cancer models that faithfully simulate their human counterparts," he said.

In addition, the VICC's proposal also included work in three "core labs" in the areas of pathology (Drs. Kay Washington, Roy Jensen and Scott Shappell), eicosanoid research (Dr. Jason Morrow and Alan Brash), and imaging using mass spectrometry (Dr. Richard Caprioli) and DNA microarray analysis (Drs. Coffey, Threadgill and Rick Haselton). These resources can be shared by all the VICC investigators and might also be shared with other institutions' representatives in the Consortium.

The VICC project also includes a "consortium within a consortium" that will focus on the development of a mouse model for pancreatic cancer. This project is headed up by Steve Leach, M.D., associate professor of Surgery and Cell Biology.

The proposal also called attention to the recent formation of the Tennessee Mouse Genome Consortium - including Vanderbilt Medical Center, Oak Ridge National Laboratories, Meharry Medical College, St. Jude Children's Research Hospital and the University of Tennessee - to collaborate on work to determine the functions of genes. "While this is an institutional grant, we cited the development of that project as a strength that Vanderbilt brings," Coffey said.

The NCI Consortium will conduct its work through two annual meetings each year, augmented by meetings of "subgroups" focused on specific areas of interest and electronic communication through a special website. "For instance, a pathology subgroup has already formed to prioritize the needs in that field to support the work of the consortium," Coffey said. "They might, for instance, articulate the need for more pathologists with expertise in comparative mouse pathology and human pathology. The NCI, in turn, might then set aside significant dollars for training people with that combined expertise."

Next year, the NCI plans to activate an Internet site with information about the Consortium, its activities and its progress.

The Consortium recently kicked off its work with a nearly three-day meeting at the NCI, attended by both Klausner and Dr. Harold Varmus, outgoing director of the National Institutes of Health, Coffey said.

"We're very excited about the opportunities that this Consortium presents," Coffey said. "It's terrific that Vanderbilt scored as high as it did. We have a very relevant molecule in the type 2 TGFb receptor - it appears to be very important in human cancers - and we have unique technologies at Vanderbilt to study the models we develop in these four common human cancers. "It places Vanderbilt at the forefront of institutions in this important area. It's nice to have a seat at the table."
-end-
As one of a select group of National Cancer Institute-designated cancer centers, the Vanderbilt-Ingram Cancer Center is a recognized leader in cancer research, treatment and prevention. The VICC is one of only a few NCI-designated centers in the southeast and the only one in Tennessee dedicated to providing the most promising therapies and advancing research in all types of cancer in adults and children. Its clinical trials program reaches into local communities through a network of more than a dozen affiliate hospitals in Tennessee, Kentucky and Alabama. For more information, visit the VICC website at www.vanderbiltcancer.org.

Vanderbilt University Medical Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.